Document is current
Any future updates will be listed below
-
Authors
Abay, Tsion
Stickels, Robert R. https://orcid.org/0000-0003-4326-4084
Takizawa, Meril T.
Nalbant, Benan N.
Hsieh, Yu-Hsin
Hwang, Sidney
Snopkowski, Catherine
Yu, Kenny Kwok Hei https://orcid.org/0000-0002-2394-4990
Abou-Mrad, Zaki https://orcid.org/0000-0001-6387-8396
Tabar, Viviane https://orcid.org/0000-0002-1284-1670
Howitt, Brooke E. https://orcid.org/0000-0002-0309-6680
Ludwig, Leif S. https://orcid.org/0000-0002-2916-2164
Chaligné, Ronan https://orcid.org/0000-0003-4332-3291
Satpathy, Ansuman T. https://orcid.org/0000-0002-5167-537X
Lareau, Caleb A. https://orcid.org/0000-0003-4179-4807
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R00HG012579, UM1HG012076)
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 18 November 2024
First Online: 8 January 2025
Competing interests
: A.T.S. is a founder of Immunai, Cartography Biosciences, Santa Ana Bio and Prox Biosciences, an advisor to Wing Venture Capital and receives research funding from Astellas and Merck Research Laboratories. R.R.S., L.S.L. and C.A.L. are consultants to Cartography Biosciences. R.C. is a consultant for Sanavia Oncology, S2 Genomics and LevitasBio. The other authors declare no competing interests.
